An Observational, Prospective Cohort Study to Evaluate Safety of Remsima® Subcutaneous in Patients With Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis
NCT: NCT05866614 ·
Status: ACTIVE NOT RECRUITING ·
Phase: N/A
· Sponsor: Celltrion
· Started: 2023-01-13
· Est. Completion: 2027-03
Official Summary
This is an observational, prospective cohort study to evaluate the safety of Remsima® SC in the treatment of RA, AS, PsA and Ps.
Study Design
- Study Type: OBSERVATIONAL
- Enrollment: 881 participants
Interventions
- DRUG: Remsima IV — Patient will be treated with Remsima IV as per the SmPC or
- DRUG: Remsima SC — Patient will be treated with Remsima SC as per the SmPC
Primary Outcomes
- evaluation of adverse events of special interest (AESI) (through study completion, an average of 2 years)
Trial Locations
- CHU Purpan Hôpital Pierre Paul Riquet, Toulouse, France, France
More Rheumatoid Arthritis Trials
AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.